The Zdorovye.ru platform was launched in nine CIS countries: Uzbekistan, Kazakhstan, Armenia, Azerbaijan, Belarus, Kyrgyzstan, Moldova, Tajikistan and Turkmenistan. This was told to RB.RU by the founder and CEO of Zdorovye.ru, Eric Brovko.

The Zdorovye.ru platform was launched in nine CIS countries

Now residents of these countries can use the Zdorovye.ru application, and at the end of October an application for doctors will also be launched.

“They invested [в запуск] about 10 million rubles and we plan to invest another 20 million rubles until the end of 2024,” Brovko said.

The company will invest the funds received from investors in the first quarter of 2023.

Zdorovye.ru is a Russian developer of an online digital therapy platform for people with chronic diseases. For users in the CIS, the service offers support programs for 8 nosologies, including diabetes mellitus, heart diseases, gastrointestinal diseases (IBS, GERD, IBD, gastritis), childhood neurology, psychological diseases, lung diseases (asthma and COPD) , skin diseases. (psoriasis, atopic dermatitis) and strokes.

According to its own data, Zdorovye.ru has more than 650 thousand patients and 70 thousand monthly active users. 8 thousand doctors cooperate with the platform. Among its partners, the company names Abbott, AstraZeneca, Bayer, Biocad, Dr. Reddy’s, Janssen, Takeda, Roche, Sanofi, OlainFarm.

All services and companies related to moving on a single map

Author:

Anastasia Marina

Source: RB

Previous articleA Russian businessman tries in court to obtain the rights to the Sega brand in the Russian Federation
Next articleThe Dream Island operator wants to recover 3.5 billion rubles from the Adidas subsidiary through the courts.
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.

LEAVE A REPLY

Please enter your comment!
Please enter your name here